EIGREiger BioPharmaceuticalsEIGR info
$8.50info6.25%24h
Global rank31986
Market cap$12.58M
Change 7d6.25%
YTD Performance23.19%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Business data

    Eiger BioPharmaceuticals (EIGR) Stock Overview

    Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

    EIGR Stock Information

    Symbol
    EIGR
    Address
    2155 Park BoulevardPalo Alto, CA 94306United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.eigerbio.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    650 272 6138

    Eiger BioPharmaceuticals (EIGR) Price Chart

    -
    Value:-

    Eiger BioPharmaceuticals Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $8.50
    N/A
    Market Cap
    $12.58M
    N/A
    Shares Outstanding
    1.48M
    N/A
    Employees
    56.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org